Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)
Conventional staging methods are inadequate to identify patients with stage II colon cancer (CC) who are at high risk of recurrence after surgery with curative intent. ColDx is a gene expression, microarray-based assay shown to be independently prognostic for recurrence-free interval (RFI) and overall survival in CC. The objective of this study was to further validate ColDx using formalin-fixed, paraffin-embedded specimens collected as part of the Alliance phase III trial, C9581.
Our conclusion is that ColDx is associated with RFI in the C9581 subsample in the presence of other prognostic factors, includingMMRdeficiency. ColDx could be incorporated with the traditional clinical markers of risk to refine patient prognosis.View Resource
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.